Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Kalendar
Skriner
Yangiliklar
Biz haqimizda

SDGR - Schrödinger, Inc. So'nggi Yangiliklar | Finranks

Home

/

SDGR

S

Schrödinger, Inc. (SDGR)

NMS – Real vaqt narxi. Valyuta: USD

18.57

-0.09 (-0.46%)

Bozor ochiq: Aug 12, 2026, 11:40 AM EDT

18.43

-0.22 (-1.18%)

Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Schrödinger, Inc. (SDGR) Q2 2026 Earnings Call Transcript

Schrödinger, Inc. (SDGR) Q2 2026 Earnings Call Transcript

Schrödinger, Inc. (SDGR) Q2 2026 Earnings Call Transcript

Schrodinger Q2 Earnings Call Highlights

Schrodinger Q2 Earnings Call Highlights

Schrodinger NASDAQ: SDGR said second-quarter annual contract value growth accelerated as demand broadened across large pharmaceutical customers, biotechnology companies and materials-science customers, while the company launched early access for Bunsen, its agentic AI co-scientist.

Schrodinger, Inc. (SDGR) Q2 Earnings and Revenues Top Estimates

Schrodinger, Inc. (SDGR) Q2 Earnings and Revenues Top Estimates

Schrodinger, Inc. (SDGR) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of a loss of $0.6 per share. This compares to a loss of $0.59 per share a year ago.

Schrödinger Reports Second Quarter 2026 Financial Results

Schrödinger Reports Second Quarter 2026 Financial Results

NEW YORK--(BUSINESS WIRE)---- $SDGR #AI--Today Schrödinger announced financial results for the quarter ended June 30, 2026.

Schrödinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery

Schrödinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery

NEW YORK--(BUSINESS WIRE)-- #AgenticAI--Schrödinger, Inc. announced a strategic agreement with BMS to deploy Bunsen, Schrödinger's agentic AI co-scientist, within its research organization.

Schrodinger: A Rare AI-Adjacent Disruptor Still Not Priced For It

Schrodinger: A Rare AI-Adjacent Disruptor Still Not Priced For It

Schrödinger is challenging the incumbent drug-trial method—physics-simulated molecular design that cuts the cost, time, and animal testing of building and screening thousands of candidates. The current EV is roughly accounted for by the software leg alone - the royalties business and the disruption TAM are barely priced in, if at all. Three drivers - a regulatory push away from animal testing, AI-led consumption growth, and Bunsen - open up asymmetric upside that is not required for the base case.

Videolar

No Data

There is no data to display

Press-relizlar

Schrödinger Reports Second Quarter 2026 Financial Results

Schrödinger Reports Second Quarter 2026 Financial Results

NEW YORK--(BUSINESS WIRE)---- $SDGR #AI--Today Schrödinger announced financial results for the quarter ended June 30, 2026.

Schrödinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery

05.08.2026

Schrödinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery

NEW YORK--(BUSINESS WIRE)-- #AgenticAI--Schrödinger, Inc. announced a strategic agreement with BMS to deploy Bunsen, Schrödinger's agentic AI co-scientist, within its research organization.